Phase I/II Trial of Palbociclib, Pembrolizumab, and Letrozole in Patients with Hormone Receptor-Positive Metastatic Breast Cancer

Journal Article
Written by Simran Padam

European Journal of Cancer

A Phase I/II study evaluating palbociclib, pembrolizumab, and letrozole in hormone receptor-positive metastatic breast cancer.

View publication ↗

Simran Padam
Previous

The Role of Oncology Biomarkers in Personalizing Hematology Treatment Plans
Next

Characteristics Associated with Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults